全文获取类型
收费全文 | 241587篇 |
免费 | 19000篇 |
国内免费 | 348篇 |
专业分类
耳鼻咽喉 | 1796篇 |
儿科学 | 9796篇 |
妇产科学 | 7315篇 |
基础医学 | 30027篇 |
口腔科学 | 5003篇 |
临床医学 | 30898篇 |
内科学 | 40817篇 |
皮肤病学 | 4100篇 |
神经病学 | 25031篇 |
特种医学 | 9536篇 |
外科学 | 31701篇 |
综合类 | 2658篇 |
现状与发展 | 3篇 |
一般理论 | 214篇 |
预防医学 | 26374篇 |
眼科学 | 7223篇 |
药学 | 16273篇 |
中国医学 | 469篇 |
肿瘤学 | 11701篇 |
出版年
2023年 | 6318篇 |
2022年 | 6930篇 |
2021年 | 8031篇 |
2020年 | 8625篇 |
2019年 | 6424篇 |
2018年 | 8751篇 |
2017年 | 9220篇 |
2016年 | 8893篇 |
2015年 | 7175篇 |
2014年 | 12747篇 |
2013年 | 12335篇 |
2012年 | 12641篇 |
2011年 | 12348篇 |
2010年 | 10089篇 |
2009年 | 9919篇 |
2008年 | 10610篇 |
2007年 | 10815篇 |
2006年 | 9980篇 |
2005年 | 8919篇 |
2004年 | 8351篇 |
2003年 | 7730篇 |
2002年 | 7416篇 |
2001年 | 7084篇 |
2000年 | 6482篇 |
1999年 | 6133篇 |
1998年 | 2962篇 |
1997年 | 2538篇 |
1996年 | 2490篇 |
1995年 | 1635篇 |
1994年 | 1373篇 |
1993年 | 1159篇 |
1992年 | 3368篇 |
1991年 | 3093篇 |
1990年 | 2980篇 |
1989年 | 2783篇 |
1988年 | 2571篇 |
1987年 | 1424篇 |
1986年 | 570篇 |
1985年 | 761篇 |
1984年 | 826篇 |
1983年 | 593篇 |
1982年 | 710篇 |
1981年 | 662篇 |
1980年 | 586篇 |
1979年 | 520篇 |
1978年 | 465篇 |
1977年 | 356篇 |
1976年 | 402篇 |
1974年 | 343篇 |
1973年 | 317篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Health Policy and Technology》2022,11(2):100574
Objective: Since the COVID-19 pandemic, many governments globally have introduced policy measures to contain the spread of the virus. Popular COVID-19 containment measures include lockdowns of various forms (aggregated into government response stringency index [GRSI]) and handwashing (HWF). The effectiveness of these policy measures remains unclear in the academic literature. This study, therefore, examines the effect of government policy stringency and handwashing on total daily reported COVID-19 cases.Method: We use a comprehensive dataset of 176 countries to investigate the effect of government policy stringency and handwashing on daily reported COVID-19 cases. In this study, we apply the Lewbel (2012) two-stage least squares technique to control endogeneity.Results: Our results indicated that GRSI significantly contributes to the increase in the total and new confirmed cases of COVI-19. Sensitivity analyses revealed that the 1st, 4th, and 5th quintiles of GRIS significantly reduce total confirmed cases of COVID-19. Also, the result indicated that while the 1st quintile of GRIS contributes significantly to reducing the new confirmed cases of COVID-19, the 3rd, 4th, and 5th quintiles of GRSI contribute significantly to increasing the new confirmed cases of COVID-19. The results indicated that HWF reduces total and new confirmed cases of COVID-19; however, such effect is not robust to income and regional effects. Nonlinear analysis revealed that while GRSI has an inverted U-shaped relationship with total and new confirmed cases of COVID-19, HWF has a U-shaped relationship.Conclusion: We suggest that policymakers should focus on raising awareness and full engagement of all members of society in implementing public health policies rather than using stringent lockdown measures. 相似文献
2.
3.
4.
5.
6.
7.
《Clinical therapeutics》2022,44(3):403-417.e6
PurposeEntecavir (ETV) and tenofovir disoproxil fumarate (TDF) are both recommended as first-line treatments for patients with chronic hepatitis B virus (CHB) infection according to international HBV treatment guidelines. However, recent studies reported conflicting results regarding the preferred antiviral in the prevention of hepatocellular carcinoma (HCC). This cohort study aimed to investigate this issue by using Taiwan's National Health Insurance Research Database, wherein a “finite” but not life-long treatment policy was applied.MethodsFrom January 2008 to December 2013, a total of 12,388 consecutive adult patients with CHB who received a finite course of TDF treatment (n = 1250) or ETV treatment (n = 11,138) were analyzed through screening for study eligibility followed by the 1:4 propensity score matching method.FindingsIn the entire cohort, the annual incidence and survival between the ETV and TDF groups were not significantly different regarding HCC occurrence (2.05 vs 2.74 per 100 patient-years [PY]; P = 0.055; hazard ratio [HR], 0.975; log-rank, P = 0.966), cirrhosis-related complications (1.9 vs 2.4 per 100 PY; P = 0.149; HR, 0.869; log-rank, P = 0.388), or all-cause mortality (2.16 vs 1.6 per 100 PY; P = 0.119; HR, 0.831; log-rank, P = 0.342), respectively. Propensity score matching analyses yielded similar results regarding HCC occurrence, cirrhosis-related complications, and all-cause mortality. In addition, these findings were consistently reproduced in the subgroups of patients with chronic hepatitis and cirrhosis that developed before antiviral treatment.ImplicationsETV and TDF did not significantly differ in prevention of HCC occurrence or reduction of cirrhosis-related complications and all-cause mortality in patients with CHB receiving a finite period of treatment. 相似文献
8.
9.
《Journal of pharmaceutical sciences》2023,112(8):2212-2222
For supersaturating formulations of BCS-II compounds, which by definition have high intestinal permeability, a closed USP apparatus does not provide the necessary absorptive conditions during dissolution. To address this, an artificial gut simulator (AGS) has been constructed consisting of a 2.5 mL donor compartment in which a hollow fiber-based absorption module is suspended. Drug from donor diffuses across the hollow fiber membrane to be absorbed by the continuously flowing intraluminal receiver fluid. The membrane surface area and intraluminal fluid flow rate are tuned to obtain the physiologically observed absorption rate constant for a weakly basic, poorly water-soluble model compound, ketoconazole (KTZ). Supersaturated solutions of KTZ were generated in the donor in pH 6.5 phosphate buffer by the pH-shift method in the absence (closed system, control) and presence (open system, biorelevant) of an optimally or suboptimally tuned absorption module. Drug concentrations in the donor and intraluminal fluids were determined by in-line UV spectroscopy. The presence of an absorptive sink reduced the supersaturated solution's crystallization propensity, more so in the case of the optimally tuned AGS. This study demonstrates the significance of simulating absorption of drug at a physiological rate during dissolution studies, especially to predict the performance of formulations of BCS-II drugs. 相似文献
10.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献